Total Payments
$108,563
2024 Payments
$7,319
Companies
9
Transactions
28
Medicare Patients
3,687
Medicare Billing
$285,630
Payment Breakdown by Category
Research$89,966 (82.9%)
Consulting$15,688 (14.5%)
Other$2,730 (2.5%)
Travel$91.19 (0.1%)
Education$84.81 (0.1%)
Food & Beverage$4.14 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $89,966 | 11 | 82.9% |
| Consulting Fee | $15,688 | 8 | 14.5% |
| Honoraria | $2,360 | 1 | 2.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $369.54 | 1 | 0.3% |
| Travel and Lodging | $91.19 | 2 | 0.1% |
| Education | $84.81 | 4 | 0.1% |
| Food and Beverage | $4.14 | 1 | 0.0% |
Payments by Type
Research
$89,966
11 transactions
General
$18,597
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ONQUALITY PHARMACEUTICALS (USA) LLC | $49,475 | 6 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $34,796 | 7 | $0 (2023) |
| Lilly USA, LLC | $13,495 | 1 | $0 (2018) |
| Eli Lilly and Company | $6,800 | 4 | $0 (2024) |
| ADC Therapeutics America, Inc. | $2,360 | 1 | $0 (2022) |
| Biogen, Inc. | $1,088 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $464.87 | 4 | $0 (2024) |
| PFIZER INC. | $45.81 | 3 | $0 (2024) |
| Chiesi USA, Inc. | $39.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,319 | 10 | Eli Lilly and Company ($6,800) |
| 2023 | $27,907 | 5 | Novartis Pharmaceuticals Corporation ($26,377) |
| 2022 | $34,969 | 10 | ONQUALITY PHARMACEUTICALS (USA) LLC ($25,802) |
| 2021 | $24,873 | 2 | ONQUALITY PHARMACEUTICALS (USA) LLC ($22,173) |
| 2018 | $13,495 | 1 | Lilly USA, LLC ($13,495) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | Chiesi USA, Inc. | FILSUVEZ (Drug) | Education | Cash or cash equivalent | $39.00 | General |
| Category: DERMATOLOGY | ||||||
| 10/17/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 09/06/2024 | PFIZER INC. | CIBINQO (Drug) | Education | In-kind items and services | $15.27 | General |
| Category: Inflammation & Immunology | ||||||
| 08/30/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 06/03/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 04/30/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $5.76 | General |
| 04/30/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $4.14 | General |
| 04/12/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $369.54 | General |
| 01/25/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $85.43 | General |
| 09/09/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | Cash or cash equivalent | $509.29 | Research |
| Study: BYL-AB -117225-Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (ABC) treated with alpelisib (ALP)-FALLCDC • Category: Oncology | ||||||
| 06/29/2023 | PFIZER INC. | CIBINQO (Drug) | Education | In-kind items and services | $15.27 | General |
| Category: Inflammation & Immunology | ||||||
| 06/13/2023 | PFIZER INC. | CIBINQO (Drug) | Education | In-kind items and services | $15.27 | General |
| Category: Inflammation & Immunology | ||||||
| 02/03/2023 | ONQUALITY PHARMACEUTICALS (USA) LLC | — | — | Cash or cash equivalent | $1,500.00 | Research |
| 01/31/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | Cash or cash equivalent | $25,867.57 | Research |
| Study: Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated with Alpelisib-Breast Cancer Res Treat • Category: Oncology | ||||||
| 11/18/2022 | ONQUALITY PHARMACEUTICALS (USA) LLC | — | — | Cash or cash equivalent | $2,935.00 | Research |
| Study: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II) | ||||||
| 09/30/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | PIQRAY (Drug) | — | In-kind items and services | $443.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 09/21/2022 | ONQUALITY PHARMACEUTICALS (USA) LLC | — | — | Cash or cash equivalent | $11,064.00 | Research |
| Study: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II) | ||||||
| 08/31/2022 | ONQUALITY PHARMACEUTICALS (USA) LLC | — | — | Cash or cash equivalent | $475.00 | Research |
| Study: Unpublished research | ||||||
| 08/19/2022 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,087.50 | General |
| 07/14/2022 | ADC Therapeutics America, Inc. | — | Honoraria | Cash or cash equivalent | $2,360.00 | General |
| 06/14/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | PIQRAY (Drug) | — | In-kind items and services | $176.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 06/10/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2022 | ONQUALITY PHARMACEUTICALS (USA) LLC | — | — | Cash or cash equivalent | $11,328.00 | Research |
| Study: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II) | ||||||
| 03/30/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II) | ONQUALITY PHARMACEUTICALS (USA) LLC | $47,500 | 4 |
| Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated with Alpelisib-Breast Cancer Res Treat | Novartis Pharmaceuticals Corporation | $25,868 | 1 |
| AN OPEN-LABEL, PROOF-OF-CONCEPT STUDY OF IXEKIZUMAB IN THE TREATMENT OF PYODERMA GANGRENOSUM | Lilly USA, LLC | $13,495 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $619.00 | 2 |
| BYL-AB -117225-Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (ABC) treated with alpelisib (ALP)-FALLCDC | Novartis Pharmaceuticals Corporation | $509.29 | 1 |
| Unpublished research | ONQUALITY PHARMACEUTICALS (USA) LLC | $475.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 810 | 1,341 | $243,874 | $60,788 |
| 2022 | 15 | 922 | 1,518 | $287,951 | $75,491 |
| 2021 | 15 | 953 | 1,431 | $290,465 | $80,661 |
| 2020 | 19 | 1,002 | 1,515 | $286,586 | $68,690 |
Total Patients
3,687
Total Services
5,805
Medicare Billing
$285,630
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 234 | 325 | $69,875 | $19,582 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 136 | 206 | $62,830 | $18,543 | 29.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 104 | 125 | $30,000 | $5,168 | 17.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 48 | 52 | $18,460 | $3,741 | 20.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 32 | 33 | $12,705 | $3,385 | 26.6% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 20 | 45 | $9,225 | $1,843 | 20.0% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Office | 2023 | 68 | 68 | $9,520 | $1,687 | 17.7% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 16 | 17 | $7,480 | $1,538 | 20.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 71 | 310 | $7,750 | $1,424 | 18.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 17 | 17 | $4,965 | $1,394 | 28.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 17 | $3,655 | $997.12 | 27.3% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 13 | 13 | $3,250 | $853.32 | 26.3% |
| 11104 | Punch biopsy, first skin growth | Facility | 2023 | 15 | 15 | $3,375 | $552.90 | 16.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 25 | 98 | $784.00 | $78.70 | 10.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 165 | 275 | $74,785 | $25,001 | 33.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 245 | 346 | $64,595 | $20,831 | 32.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 104 | 130 | $30,545 | $5,443 | 17.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 65 | 71 | $25,205 | $5,170 | 20.5% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 14 | 14 | $14,560 | $3,203 | 22.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 24 | 25 | $8,500 | $2,675 | 31.5% |
| 99451 | Telephone or internet assessment with written report by consulting physician, 5 minutes or more | Office | 2022 | 102 | 103 | $14,420 | $2,441 | 16.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 27 | 27 | $7,320 | $2,055 | 28.1% |
| 96900 | Application of ultraviolet light to skin | Office | 2022 | 13 | 117 | $11,115 | $1,807 | 16.3% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2022 | 20 | 42 | $8,395 | $1,637 | 19.5% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 20 | 20 | $8,805 | $1,534 | 17.4% |
About Dr. Benjamin Kaffenberger, MD
Dr. Benjamin Kaffenberger, MD is a Dermatology healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2010. The National Provider Identifier (NPI) number assigned to this provider is 1073833042.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Kaffenberger, MD has received a total of $108,563 in payments from pharmaceutical and medical device companies, with $7,319 received in 2024. These payments were reported across 28 transactions from 9 companies. The most common payment nature is "" ($89,966).
As a Medicare-enrolled provider, Kaffenberger has provided services to 3,687 Medicare beneficiaries, totaling 5,805 services with total Medicare billing of $285,630. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Columbus, OH
- Active Since 06/01/2010
- Last Updated 02/26/2021
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1073833042
Products in Payments
- PIQRAY (Drug) $34,796
- TALTZ (Drug) $13,495
- CIBINQO (Drug) $45.81
- FILSUVEZ (Drug) $39.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Columbus
Dr. Michael Sheehan, M.d, M.D
Dermatology — Payments: $311,374
Dermatology $311,374
Stephanie Fabbro, M.d, M.D
Dermatology — Payments: $78,097
Dermatology $78,097
Dr. Shari Hicks-Graham, M.d, M.D
Dermatology — Payments: $74,753
Dermatology $74,753
Dr. Jessica Kaffenberger, M.d, M.D
Dermatology — Payments: $64,937
Dermatology $64,937
Peter Neidenbach, Md, MD
Dermatology — Payments: $40,935
Dermatology $40,935
Dr. Benjamin Bogucki, M.d, M.D
Dermatology — Payments: $23,666
Dermatology $23,666